Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 8/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 9/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11027934 | 1.00 | S1PR5 (0.60) | S1PR5ENPP2HRH3MCHR1 | |
| SCHEMBL12471153 | 1.00 | S1PR5 (0.60) | S1PR5ENPP2HRH3MCHR1 | |
| SCHEMBL19831707 | 0.96 | S1PR5 (0.56) | S1PR5ENPP2HRH3 | |
| SCHEMBL16309019 | 0.96 | S1PR5 (0.56) | S1PR5ENPP2HRH3 | |
| SCHEMBL12471114 | 0.96 | S1PR5 (0.56) | S1PR5ENPP2HRH3 | |
| SCHEMBL19272376 | 0.94 | S1PR5 (0.58) | S1PR5ENPP2 | |
| SCHEMBL11032357 | 0.94 | S1PR5 (0.58) | S1PR5ENPP2 | |
| SCHEMBL11027772 | 0.94 | S1PR5 (0.58) | S1PR5ENPP2 | |
| SCHEMBL11942501 | 0.94 | S1PR5 (0.58) | S1PR5ENPP2 | |
| SCHEMBL1162014 | 0.94 | S1PR5 (0.58) | S1PR5ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660010-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2022-07-27 | — | — | EP | claimed |
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | claimed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | claimed |
| US-20200038385-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2020-02-06 | — | — | US | claimed |
| EP-3150590-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2019-10-16 | — | — | EP | claimed |
| US-10406144-B2 | SIP modulating agents | BIOGEN MA INC. (US) | 2019-09-10 | — | — | US | claimed |
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2019-07-11 | — | — | US | claimed |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2019-01-01 | — | — | US | claimed |
| US-20180369215-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2018-12-27 | — | — | US | claimed |
| US-10034869-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2018-07-31 | — | — | US | claimed |
| US-9340527-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2016-05-17 | — | — | US | claimed |
| US-20160129023-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. | 2016-05-12 | — | — | US | claimed |
| US-9186367-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BOIGEN MA INC. (US) | 2015-11-17 | — | — | US | claimed |
| EP-2461683-B1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC INC (US) | 2015-04-29 | — | — | EP | claimed |
| US-20140371209-A1 | S1P Modulating Agents | BIOGEN MA INC. | 2014-12-18 | — | — | US | claimed |
| US-20140309190-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2014-10-16 | — | — | US | claimed |
| US-8802659-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2014-08-12 | — | — | US | claimed |
| EP-2672823-A1 | S1P MODULATING AGENTS | Biogen Idec MA Inc. (US) | 2013-12-18 | — | — | EP | claimed |
| WO-2012109108-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2012-08-16 | — | — | WO | claimed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038385-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | S1PR5 5/4885ENPP2 38/4885HRH3 682/4885 |
| US-20160129023-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | S1PR5 6/4885ENPP2 132/4885HRH3 601/4885 |
| US-20140371209-A1 | S1P Modulating Agents | S1PR2, S1PR1, S1PR3 | S1PR5 4/4885ENPP2 74/4885HRH3 711/4885 |
| US-20140309190-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | S1PR5 6/4885ENPP2 132/4885HRH3 601/4885 |
| US-10034869-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | S1PR5 4/4885ENPP2 52/4885HRH3 308/4885 |
| US-10406144-B2 | SIP modulating agents | S1PR2, S1PR1, S1PR3 | S1PR5 4/4885ENPP2 94/4885HRH3 803/4885 |
| US-10894040-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | S1PR5 4/4885ENPP2 56/4885HRH3 309/4885 |
| US-20180369215-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | S1PR5 5/4885ENPP2 38/4885HRH3 682/4885 |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | S1PR5 5/4885ENPP2 32/4885HRH3 613/4885 |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | S1PR5 6/4885ENPP2 132/4885HRH3 601/4885 |
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | S1PR5 5/4885ENPP2 32/4885HRH3 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.